What happened with BHC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bausch Health sells medicines for conditions including digestive, neurological and skin disorders, alongside eye-health products. It earns most of its revenue from selling products to wholesalers and other customers, with some direct sales to hospitals, physicians and pharmacy chains. Cencora, McKesson and Cardinal Health together account for a substantial share of revenue. Insurance and government coverage help determine whether patients use certain medicines and what the company ultimately earns from them.
Its majority-owned Bausch + Lomb business is its largest revenue contributor, selling contact lenses, eye medications and equipment used in eye surgery. Bausch Health plans to separate this business, but has not completed the separation. Its next-largest business, Salix, sells gastrointestinal medicines in the United States and depends heavily on Xifaxan, used for diarrhea-predominant irritable bowel syndrome and to reduce recurrence of a brain-function disorder associated with liver disease. Solta Medical also sells aesthetic devices, mainly the Thermage skin-tightening line.
The medicine business depends on patent and regulatory protection: lower-priced generics can sharply reduce branded sales when protection ends or is successfully challenged. Bausch Health also sells generic versions of some of its own brands to retain part of that business. Government pricing rules constrain what it can charge, and promotion of its medicines is restricted to approved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bausch + Lomb's eye-care sales feed directly into Bausch Health's results: the parent owns approximately 88% and consolidates the business, which supplied half its revenue in 2025. Watch sales of contact lenses and consumer eye-care products, its largest revenue line, alongside eye medicines and surgical products.
Amneal Pharmaceuticals, Inc. is seeking approval to sell a generic version of Bausch Health's Xifaxan 550 mg, threatening a medicine that generated more than 20% of Bausch Health's revenue in both 2025 and 2024. Watch final approval and the patent case: the FDA granted tentative approval in January 2025, but final approval remained blocked by a court order.
Alcon competes for the eye-care sales that reach Bausch Health through Bausch + Lomb, selling contact lenses, ocular-health products and eye-surgery equipment and implants. Its Vision Care and Surgical sales show how a rival is performing across these same markets.
The Cooper Companies competes with Bausch Health's Bausch + Lomb through CooperVision, which sells contact lenses worldwide, particularly silicone hydrogel lenses. Watch CooperVision's new lens launches and sales as demand shifts toward silicone hydrogel products and away from older lens lines.
Teva sells generic medicines in competition with Bausch Health, and its Xifaxan patent settlement gives it generic-entry rights that matter to Bausch Health's major drug franchise. Watch news affecting those rights: Bausch Health says generic rifaximin entering before January 2028 could materially affect its business.
Johnson & Johnson's vision business competes with Bausch Health's Bausch + Lomb for contact-lens sales and equipment used to correct patients' vision through refractive surgery. Watch its silicone hydrogel lens offerings and corneal laser-surgery equipment, where the businesses overlap.
AbbVie competes with several Bausch Health businesses: its Linzess rivals Trulance, Restasis rivals dry-eye medicines, and its aesthetics portfolio competes with Solta treatments. The overlap spans medicines sold to patients and aesthetic treatments, rather than a single product market.
Viatris competes with Bausch Health for prescriptions and access to distributors across international markets, where both sell established branded medicines and generics. The overlap is in these mature medicine businesses, rather than Bausch Health's eye-care or aesthetic devices.
Bausch Health Companies Inc earningsThis company
Bausch Health’s report will show how much of its drug and eye-care sales growth remains after sales deductions, operating costs and interest.
Read net sales alongside segment profit margins and operating cash flow, and keep interest payments in view. Sales growth with steady margins and operating cash remaining after interest would show that growth is converting into cash for the business and debt service. If sales rise but margins or cash flow weaken, discounts, operating costs or interest are absorbing the growth.
Bausch + Lomb Corporation earningsBLCO
Bausch + Lomb’s report will show how the eye-care business that contributes half of Bausch Health’s revenue is doing in contact lenses, consumer eye care, medicines and surgical products.
Compare sales of contact lenses and consumer eye-care products with sales of eye medicines and surgical products. Strength in the first two alongside growth in the latter would show that broad parts of Bausch + Lomb’s business are contributing to Bausch Health’s revenue; weakness in its main sales lines would pressure this major source of consolidated revenue.
Alcon Inc. earningsALC
Alcon’s report will show how its contact lenses, ocular-health products and eye-surgery products are selling in markets it shares with Bausch Health’s Bausch + Lomb.
Watch sales in Alcon’s Vision Care and Surgical businesses, especially contact lenses and eye-surgery products. Growth in both would show demand supporting a rival in markets Bausch + Lomb also serves; weaker sales would point to less momentum for Alcon in those shared markets, but would not establish Bausch + Lomb’s own sales.
